Merck’s new HPV vaccine could rejuvenate market, says GlobalData
Despite being hampered both by apathy and resistance in recent years, the human papillomavirus (HPV) vaccine market is expected to receive an additional boost from US pharma giant Merck & Co’s (NYSE: MRK) novel candidate V503.
The drug candidate offers protection against five HPV types not covered by current vaccines; however, effective marketing efforts must be made to ensure sufficient uptake of this new product, says an analyst with research and consulting firm GlobalData.
Recently, Merck announced that V503 has performed well in Phase III trials, demonstrating 97% efficacy against precancerous lesions caused by the additional five HPV types it contains (The Pharma Letter November 6).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze